Stockscreener 앱 받기
1.99
11.16%
-0.25
전일 마감가:
$2.24
열려 있는:
$2.23
하루 거래량:
224.00K
Relative Volume:
0.34
시가총액:
$59.16M
수익:
-
순이익/손실:
$-21.24M
주가수익비율:
-2.375
EPS:
-0.8379
순현금흐름:
$-22.47M
1주 성능:
+4.19%
1개월 성능:
+53.08%
6개월 성능:
-62.80%
1년 성능:
-84.72%
1일 변동 폭
$1.98
$2.2999
1주일 범위
$1.865
$2.2999
52주 변동 폭
$1.14
$13.51
Skye Bioscience Inc Stock (SKYE) Company Profile
명칭
Skye Bioscience Inc
전화
(858) 410-0266
주소
11250 EL CAMINO REAL, SUITE 100, SAN DIEGO
SKYE을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SKYE
Skye Bioscience Inc.
|
3.10 | 12.89M | 0 | 0 | 0 | 0.00 |
|
GOODO
Gladstone Commercial Corporation
|
20.26 | 372.90M | 0 | 0 | 0 | 0.00 |
|
PSNYW
Polestar Automotive Holding Uk
|
0.1555 | 349.69M | 2.07B | -1.42B | -1.37B | -0.6765 |
|
MOBBW
Mobilicom Limited Warrants
|
0.2267 | 318.40M | 0 | 0 | 0 | 0.00 |
|
JUNE
Dhandho Junoon Etf
|
11.00 | 205.55M | 0 | 0 | 0 | 0.00 |
|
SHMD
Schmid Group N V
|
4.11 | 157.18M | 0 | 0 | 0 | 0.00 |
Skye Bioscience Inc Stock (SKYE) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-02-28 | 개시 | William Blair | Outperform |
| 2024-09-30 | 개시 | Scotiabank | Sector Outperform |
| 2024-09-10 | 개시 | JMP Securities | Mkt Outperform |
| 2024-07-09 | 개시 | Craig Hallum | Buy |
| 2024-05-23 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-04-12 | 개시 | Oppenheimer | Outperform |
모두보기
Skye Bioscience Inc 주식(SKYE)의 최신 뉴스
Levi & Korsinsky Investigates Possible Securities Fraud Violations by Skye Bioscience, Inc. (SKYE) - ACCESS Newswire
Skye Bioscience, Inc. (NASDAQ:SKYE) Holdings Increased by Geode Capital Management LLC - Defense World
Geode Capital Management LLC Has $1.15 Million Stake in Skye Bioscience, Inc. (NASDAQ:SKYE) - Defense World
Skye Bioscience to Participate in May Investment and Medical Conferences - GlobeNewswire
Clinical-Stage Biotech Skye Sets Triple Conference Schedule: Key Obesity Drug Updates Coming in May - Stock Titan
Skye Bioscience (SKYE) Grants Stock Options to New Employee | SK - GuruFocus
Press Release Distribution & PR Platform - ACCESS Newswire
Skye Bioscience Board Approves 19,000 Share Options Grant Under 2024 Inducement Plan - Stock Titan
Skye Bioscience Grants Stock Options to New Employee Under 2024 Inducement Equity Incentive Plan - Nasdaq
Skye Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Skye Bioscience stock target holds at $15 on obesity drug outlook - Investing.com
SIMPLY BETTER BRANDS ANNOUNCES RESULTS FOR FISCAL 2024, HIGHLIGHTING 77% INCREASE IN TRUBAR™ REVENUE, AND CORPORATE NAME CHANGE TO TRUBAR INC. - The Globe and Mail
William Blair Forecasts Skye Bioscience Q2 Earnings - MarketBeat
(04/22/25) SKYE: A Speculative Play in the Weight Loss Drug Space - moneyshow.com
SKYE’s Market Ups and Downs: What’s Behind the 2023 Stock Performance? - investchronicle.com
Skye Bioscience, Inc. (NASDAQ:SKYE) Given Average Rating of “Buy” by Analysts - Defense World
William Blair Predicts Skye Bioscience Q1 Earnings - Defense World
Brokers Offer Predictions for Skye Bioscience Q1 Earnings - Defense World
Analysts Set Skye Bioscience, Inc. (NASDAQ:SKYE) PT at $16.60 - Defense World
Brokers Issue Forecasts for Skye Bioscience Q2 Earnings - Defense World
Mural's Big Shake-Up, Skye's Weight Loss Win, And Janover's Crypto Bet - Finimize
A Weight Loss Drug Candidate Essentially For Free As Skye Bioscience Is Trading At Cash Value - Seeking Alpha
Skye Bioscience reports promising obesity treatment study By Investing.com - Investing.com South Africa
Skye Bioscience's Obesity Candidate Shows 30% Weight Loss When Combined With Eli Lilly's Blockbuster Drug In Animal Models - Benzinga
Skye Bioscience (SKYE) Schedules Key Meetings at Biopharma Symposium - GuruFocus
Crude Oil Moves Lower; Citigroup Posts Upbeat Results - Benzinga
Skye Bioscience soars after experimental weight-loss drug shows promise in mice - TradingView
Nasdaq Surges 100 Points; Bank of America Earnings Top Views - Benzinga
Skye Bioscience Demonstrates Over 30% Weight Loss With Nimacimab And Tirzepatide Combination In Preclinical Model - marketscreener.com
Skye Bioscience's (SKYE) Nimacimab Shows Promising Weight Loss R - GuruFocus
Skye Bioscience Demonstrates Over 30% Weight Loss with Nimacimab - GuruFocus
Skye Bioscience Demonstrates Over 30% Weight Loss with Nimacimab and Tirzepatide Combination in Preclinical Model | SKYE Stock News - GuruFocus
Skye Bioscience reports promising obesity treatment study - Investing.com
Skye Bioscience Demonstrates Over 30% Weight Loss with - GlobeNewswire
Skye Bioscience (SKYE) Demonstrates Over 30% Weight Loss with Nimacimab and Tirzepatide Combination in Preclinical Model - StreetInsider
Skye Bioscience Demonstrates Over 30% Weight Loss with Nimacimab and Tirzepatide Combination in Preclinical Model - markets.businessinsider.com
Skye Bioscience to Conduct Meetings at Piper Sandler Conference - GuruFocus
Major Obesity Drug Developer Skye Bio Takes Center Stage at Prestigious Investor Conference - Stock Titan
Skye Bioscience (NASDAQ:SKYE) Shares Down 50.8% – Here’s Why - Defense World
Skye Bioscience (NASDAQ:SKYE) Trading Down 50.8% – What’s Next? - Defense World
Skye Bioscience, Inc. Investigated by Shareholder Rights AdvocatesInvestors Should Contact Levi & Korsinsky Regarding Potential Securities Law ViolationsSKYE - ACCESS Newswire
Let's Tokyo! WestJet bolsters connectivity between Calgary and Japan with new daily year-round service - The Globe and Mail
VOO ETF News, 4/4/2025 - The Globe and Mail
Charles Schwab Investment Management Inc. Has $176,000 Position in Skye Bioscience, Inc. (NASDAQ:SKYE) - Defense World
Charles Schwab Investment Management Inc. Grows Stock Position in Skye Bioscience, Inc. (NASDAQ:SKYE) - Defense World
10,142 Shares in Skye Bioscience, Inc. (NASDAQ:SKYE) Acquired by Virtu Financial LLC - Defense World
Virtu Financial LLC Invests $29,000 in Skye Bioscience, Inc. (NASDAQ:SKYE) - Defense World
Skye Bioscience Inc (SKYE) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.39%
3.66%
자본화:
|
볼륨(24시간):